1. Home
  2. RYDE vs CANF Comparison

RYDE vs CANF Comparison

Compare RYDE & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYDE
  • CANF
  • Stock Information
  • Founded
  • RYDE 2014
  • CANF 1994
  • Country
  • RYDE Singapore
  • CANF Israel
  • Employees
  • RYDE N/A
  • CANF N/A
  • Industry
  • RYDE
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • RYDE
  • CANF Health Care
  • Exchange
  • RYDE NYSE
  • CANF Nasdaq
  • Market Cap
  • RYDE 13.9M
  • CANF 14.4M
  • IPO Year
  • RYDE 2024
  • CANF N/A
  • Fundamental
  • Price
  • RYDE $0.40
  • CANF $1.97
  • Analyst Decision
  • RYDE Strong Buy
  • CANF Strong Buy
  • Analyst Count
  • RYDE 1
  • CANF 2
  • Target Price
  • RYDE $9.00
  • CANF $14.00
  • AVG Volume (30 Days)
  • RYDE 497.7K
  • CANF 65.4K
  • Earning Date
  • RYDE 12-03-2024
  • CANF 11-26-2024
  • Dividend Yield
  • RYDE N/A
  • CANF N/A
  • EPS Growth
  • RYDE N/A
  • CANF N/A
  • EPS
  • RYDE N/A
  • CANF N/A
  • Revenue
  • RYDE $5,761,982.00
  • CANF $667,000.00
  • Revenue This Year
  • RYDE $2.61
  • CANF $409.56
  • Revenue Next Year
  • RYDE $21.90
  • CANF N/A
  • P/E Ratio
  • RYDE N/A
  • CANF N/A
  • Revenue Growth
  • RYDE N/A
  • CANF N/A
  • 52 Week Low
  • RYDE $0.40
  • CANF $1.87
  • 52 Week High
  • RYDE $22.49
  • CANF $4.69
  • Technical
  • Relative Strength Index (RSI)
  • RYDE N/A
  • CANF 37.14
  • Support Level
  • RYDE N/A
  • CANF $1.90
  • Resistance Level
  • RYDE N/A
  • CANF $2.21
  • Average True Range (ATR)
  • RYDE 0.00
  • CANF 0.19
  • MACD
  • RYDE 0.00
  • CANF -0.01
  • Stochastic Oscillator
  • RYDE 0.00
  • CANF 15.00

About RYDE RYDE GROUP LTD

Ryde Group Ltd is a company providing a super mobility app offering ultimate convenience and reliability for their customers through multiple mobility tools that can be accessed and function seamlessly out of a single app. The company operates in the following segments such as being mobility where it provides on-demand and scheduled carpooling and ride-hailing services, matching riders to driver partners; and quick commerce where it provides on-demand, scheduled, and multi-stop parcel delivery services.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: